RENEURON GRP (LSE:RENE)

 

RENEURON GRP (RENE.L, LSE, LSE:RENE)

RENE Share PerformanceMore

52 week high4.3900 02/12/14
52 week low2.7500 16/06/14
52 week change -0.1250 (-3.57%)
4 week volume34,423,654 04/02/15

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Reneuron - Innovators & Investors Forum

Director Deals - ReNeuron Group PLC (RENE)

Olav Helleb, Chief Executive Officer, bought 322,778 shares in the company on the 29th January 2015 at a price of 3.10p. Th...

Director Deals - ReNeuron Group PLC (RENE)

Michael Hunt, Chief Executive Officer, bought 161,556 shares in the company on the 29th January 2015 at a price of 3.10p. T...

Director Share Purchases

RNS Number: 5400D ReNeuron Group plc 30 January 2015 30 January 2015 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Director Share Purchases Guildford, UK, 30 January 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, was informed on 29 January 2015 that two of its Directors acquired ordinary s...

Notification of Major Interest in Shares

RNS Number: 0633C ReNeuron Group plc 13 January 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Reneuron Group 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisitio...

Notification of Major Interest in Shares

RNS Number: 6930B ReNeuron Group plc 08 January 2015 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ReNeuron Group plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acqu...

ReNeuron widens H1 pretax loss

ReNeuron has widened its H1 pretax loss to 4.9m, from a year-earlier loss of 3.5m. Revenue was 11,000, flat on the year. Chai...

Interim Results

RNS Number: 1655X ReNeuron Group plc 17 November 2014 Details are given below of an analyst meeting and webcast at 10.00am this morning 17 November 2014 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Interim Results for the six months ended 30 September 2014 Guildford, UK, 17 November 2014: ReNeuron Group plc (AIM: RENE), a ...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
28/11/2014
ReNeuron is facing a potentially transformational year in 2015, with key clinical data and relocation to a new cell manufacturing/research facility. Its allogeneic, CTX neural stem cell product is...
edison investment research
ReNeuron Group plc
29/09/2014
ReNeuron operates off solid fundamentals as it seeks to advance its novel stem cell technology. Last year’s £25.3m fundraise coupled with a £7.8m grant from the Welsh government to build a new...
edison investment research
ReNeuron Group plc
08/05/2014
Long-term data from the PISCES Phase I study of ReNeuron’s neural stem cell product ReN001 in 11 disabled stroke patients provide further evidence of safety and encouraging signals of efficacy. The...

Users' HoldingsMore

Users who hold RENEURON GRP also hold..
BARCLAYS13%
BP12%
LLOYDS BANKING GRP11%
ROYAL BK OF SCOTLD GRP,THE11%
GLAXOSMITHKLINE11%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE